AERIE PHARMACEUTICALS INC
Ophthalmic pharmaceuticals for glaucoma and ocular hypertension (Rocklatan and Rhopressa)
- Sector
- Biotech
- Headquarters
- Bedminster, NJ
- Latest Form D
- $125M, Sep 2014
- Total capital
- $175M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $175M
- 4 Form D · last Sep 2014
- 145 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 33
- 7 pending · first 2019
- Rank in peer group#34 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$125M
- Private capital raisedForm D · SEC · 3rd filing$3M
- Private capital raisedForm D · SEC · 2nd filing$41.4M
- Private capital raisedForm D · SEC · 1st filing$5.3M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#34 · top 2%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Mitchell deLongResearcherExecutive OfficerLinked by 2 patents
- ANAND MEHRADirectorNamed in SEC Form D filings
- BRIAN LEVYExecutive OfficerNamed in SEC Form D filings
- CASEY KOPCZYNSKIExecutive OfficerNamed in SEC Form D filings
- David EpsteinExecutive Officer, DirectorNamed in SEC Form D filings
- DAVID GRYSKADirectorNamed in SEC Form D filings
Show all 17 people
- David MackDirectorNamed in SEC Form D filings
- DENNIS J HENNERDirectorNamed in SEC Form D filings
- GEOFFREY DUYKDirectorNamed in SEC Form D filings
- GERALD CAGLEDirectorNamed in SEC Form D filings
- JAMES MAZZODirectorNamed in SEC Form D filings
- Janet ConwayDirectorNamed in SEC Form D filings
- MURRAY J GOLDBERGDirectorNamed in SEC Form D filings
- RICHARD RUBINOExecutive OfficerNamed in SEC Form D filings
- THOMAS J MITROExecutive OfficerNamed in SEC Form D filings
- Thomas van HaarlemExecutive Officer, DirectorNamed in SEC Form D filings
- VICENTE ANIDOExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 33 granted of 40- GrantedDissolvable Medicament ImplantUSPTOUS D1,072,252
- GrantedAryl Cyclopropyl-amino-isoquinolinyl Amide CompoundsUSPTOUS 12,018,012
- GrantedAryl Cyclopropyl-amino-isoquinolinyl Amide CompoundsUSPTOUS 11,891,376
Show all 40 patent records
- Dissolvable Medicament ImplantApr 22, 2025 · US D1,072,252Granted
- Aryl Cyclopropyl-amino-isoquinolinyl Amide CompoundsJun 25, 2024 · US 12,018,012Granted
- Aryl Cyclopropyl-amino-isoquinolinyl Amide CompoundsFeb 6, 2024 · US 11,891,376Granted
- Ophthalmic Pharmaceutical Compositions And Uses ThereofDec 26, 2023 · US 11,850,221Granted
- Ophthalmic CompositionsJul 25, 2023 · US 11,707,460Granted
- Isoquinoline-steroid Conjugates And Uses ThereofJul 4, 2023 · US 11,691,950Granted
- Dual Mechanism Inhibitors For The Treatment Of DiseaseApr 4, 2023 · US 11,618,748Granted
- Ophthalmic CompositionsFeb 28, 2023 · US 11,590,123Granted
- Ophthalmic CompositionsSep 29, 2022 · Application 17841433Pending
- Aryl Cyclopropyl-amino-isoquinolinyl Amide CompoundsAug 30, 2022 · US 11,427,563Granted
- Ophthalmic CompositionsJul 19, 2022 · US 11,389,441Granted
- Aryl Cyclopropyl-amino-isoquinolinyl Amide CompoundsApr 26, 2022 · US 11,312,700Granted
- Combination TherapyMar 24, 2022 · Application 17544648Pending
- Combination TherapyDec 14, 2021 · US 11,197,853Granted
- Compositions For Treating Glaucoma Or Reducing Intraocular PressureNov 30, 2021 · US 11,185,538Granted
- Intravitreal Drug Delivery Systems For The Treatment Of Ocular ConditionsSep 14, 2021 · US 11,116,776Granted
- Compounds, Compositions and Methods for Treatment of MyopiaSep 14, 2021 · US 11,117,869Granted
- Beta- And Gamma-amino-isoquinoline Amide Compounds And Substituted Benzamide CompoundsAug 19, 2021 · Application 17244786Pending
- Isoquinoline-steroid Conjugates And Uses ThereofJul 13, 2021 · US 11,059,789Granted
- Dual Mechanism Inhibitors For The Treatment Of DiseaseJun 8, 2021 · US 11,028,081Granted
- Combination TherapyJun 1, 2021 · US 11,020,385Granted
- Beta- And Gamma-amino-isoquinoline Amide Compounds And Substituted Benzamide CompoundsJun 1, 2021 · US 11,021,456Granted
- Amino-benzoisothiazole And Amino-benzoisothiadiazole Amide CompoundsMar 25, 2021 · Application 16977929Pending
- 6-AMINOISOQUINOLINE CompoundsJan 26, 2021 · US 10,899,714Granted
- Beta- And Gamma-amino-isoquinoline Amide Compounds And Substituted Benzamide CompoundsJan 5, 2021 · US 10,882,840Granted
- Aryl Cyclopropyl-amino-isoquinolinyl Amide CompoundsDec 8, 2020 · US 10,858,339Granted
- Implant Applicators And Methods Of Administering ImplantsDec 1, 2020 · US 10,849,656Granted
- Ophthalmic composition for treating dry eye and symptoms thereofOct 1, 2020 · Application 16811618Pending
- Combination TherapySep 3, 2020 · Application 16780294Pending
- Dual Mechanism Inhibitors For The Treatment Of DiseaseMay 19, 2020 · US 10,654,844Granted
- Rho Kinase InhibitorsApr 21, 2020 · US 10,624,882Granted
- Intravitreal Drug Delivery Systems For The Treatment Of Ocular ConditionsApr 21, 2020 · US 10,624,904Granted
- Combination TherapyMar 17, 2020 · US 10,588,901Granted
- Combination TherapyFeb 25, 2020 · US 10,568,878Granted
- Process For The Preparation Of Kinase Inhibitors And Intermediates ThereofFeb 4, 2020 · US 10,550,087Granted
- Beta- And Gamma-amino-isoquinoline Amide Compounds And Substituted Benzamide CompoundsJan 14, 2020 · US 10,532,993Granted
- 6-AMINOISOQUINOLINE CompoundsNov 12, 2019 · US 10,472,327Granted
- Mono-(acid) Salts Of 6-AMINOISOQUINOLINES And Uses ThereofOct 24, 2019 · Application 16370240Pending
- Dual Mechanism Inhibitors For The Treatment Of DiseaseJun 11, 2019 · US 10,316,029Granted
- Dual Mechanism Inhibitors For The Treatment Of DiseaseJan 8, 2019 · US 10,174,017Granted
Related companies, and why
- Bluejay TherapeuticsSimilar federal contract value in Biotech · null in contracts
- STINGINN, LLCSimilar federal contract value in Biotech · null in contracts
- NOVICI BIOTECH, LLCSimilar federal contract value in Biotech · null in contracts
- Gate BioscienceSimilar federal contract value in Biotech · null in contracts
- InsitroSimilar federal contract value in Biotech · null in contracts
- Nurix TherapeuticsSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .